Kazi, Dhruv S <br/><br/>
Cost-effectiveness of PCSK9 Inhibitor Therapy-Reply.  [electronic resource] 

 -  JAMA  Nov 2016 
 - 2152 p.  digital 
<br/><br/> Publication Type: Letter; Comment 
<br/><br/><label>ISSN: </label>1538-3598 
<br/><br/><label>Standard No.: </label>10.1001/jama.2016.16292  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Cost-Benefit Analysis<br/>Humans<br/>Proprotein Convertases<br/>Serine Endopeptidases